CryoPort Inc Dossier
Qualitative Analysis
Business overview
Cryoport, Inc. (NASDAQ: CYRX) is a leading global provider of integrated, temperature-controlled supply chain solutions dedicated to the life sciences industry, with a specialized focus on the rapidly expanding cell and gene therapy (CGT) market. The company operates through two primary reportable segments: Life Sciences Services and Life Sciences Products. Cryoport's comprehensive suite of solutions includes specialized cryogenic packaging (such as liquid nitrogen dry vapor shippers), advanced logistics management via its proprietary Cryoportal platform, biostorage, bioservices, and the manufacturing of cryogenic systems through its MVE Biological Solutions brand. By establishing a robust 'Chain of Compliance' framework, Cryoport ensures the regulatory integrity, safety, and traceability of high-value, temperature-sensitive biological materials from clinical trials through to global commercialization.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Established to transform Cryoport into a technology-powered life sciences platform by embedding advanced digital capabilities across all global temperature-controlled supply chain services and products.
Expected impact: Lowers operational costs, improves efficiency, and unlocks new products, services, and data-driven insights for customers by automating processes and improving visibility.
Standardizes cell processing and embeds Cryoport across the therapy lifecycle, moving the business model from pure logistics to integrated service capture at multiple revenue touchpoints.
Expected impact: Monetizes steps beyond transport and captures a larger share of commercial-stage value chains.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Belgium-based temperature-controlled supply chain solutions firm to expand coverage in Europe and provide end-to-end solutions in a highly strategic area for Pharma/BioPharma activity.
Financial impact: Financial details were not disclosed.
Acquisition of Darmstadt-based provider of integrated solutions for cold supply chain to enhance digital and hardware capabilities.
Financial impact: Financial details were not disclosed.
Strategic Partnerships
Formed in connection with DHL's acquisition of CRYOPDP from Cryoport. Designed to strengthen supply chain service offerings for the global life sciences and healthcare sectors, enhancing Cryoport's positioning in the APAC and EMEA regions.
Terms: Involved DHL acquiring 100% of CRYOPDP, providing Cryoport with a substantial capital infusion.
Collaborating to leverage Cryoport Systems' supply chain solutions in support of complementary offerings in the cell and gene therapy (CGT) space, reinforcing supply chain standardization.
Terms: Not specified
Collaborating to integrate Cryoport Systems' supply chain solutions into clinical trial management and support complementary offerings in the CGT space.
Terms: Not specified